RT Journal Article SR Electronic T1 Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.12.24.20248802 DO 10.1101/2020.12.24.20248802 A1 Hannah E. Davis A1 Gina S. Assaf A1 Lisa McCorkell A1 Hannah Wei A1 Ryan J. Low A1 Yochai Re’em A1 Signe Redfield A1 Jared P. Austin A1 Athena Akrami YR 2020 UL http://medrxiv.org/content/early/2020/12/27/2020.12.24.20248802.abstract AB Objective To characterize the symptom profile and time course in patients with Long COVID, along with the impact on daily life, work, and return to baseline health.Design International web-based survey of suspected and confirmed COVID-19 cases with illness lasting over 28 days and onset prior to June 2020.Setting Survey distribution via online COVID-19 support groups and social mediaParticipants 3,762 respondents from 56 countries completed the survey. 1166 (33.7%) were 40-49 years old, 937 (27.1%) were 50-59 years old, and 905 (26.1%) were 30-39 years old. 2961 (78.9%) were women, 718 (19.1%) were men, and 63 (1.7%) were nonbinary. 8.4% reported being hospitalized. 27% reported receiving a laboratory-confirmed diagnosis of COVID-19. 96% reported symptoms beyond 90 days.Results Prevalence of 205 symptoms in 10 organ systems was estimated in this cohort, with 66 symptoms traced over seven months. Respondents experienced symptoms in an average of 9.08 (95% confidence interval 9.04 to 9.13) organ systems. The most frequent symptoms reported after month 6 were: fatigue (77.7%, 74.9% to 80.3%), post-exertional malaise (72.2%, 69.3% to 75.0%), and cognitive dysfunction (55.4%, 52.4% to 58.8%). These three symptoms were also the three most commonly reported overall. In those who recovered in less than 90 days, the average number of symptoms peaked at week 2 (11.4, 9.4 to 13.6), and in those who did not recover in 90 days, the average number of symptoms peaked at month 2 (17.2, 16.5 to 17.8). Respondents with symptoms over 6 months experienced an average of 13.8 (12.7 to 14.9) symptoms in month 7. 85.9% (84.8% to 87.0%) experienced relapses, with exercise, physical or mental activity, and stress as the main triggers. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 45.2% (42.9% to 47.2%) reported requiring a reduced work schedule compared to pre-illness and 22.3% (20.5% to 24.3%) were not working at the time of survey due to their health conditions.Conclusions Patients with Long COVID report prolonged multisystem involvement and significant disability. Most had not returned to previous levels of work by 6 months. Many patients are not recovered by 7 months, and continue to experience significant symptom burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors are group of volunteers. Survey expenses were covered by AA's research fund from Sainsbury Wellcome Centre (Wellcome Trust and Gatsby Charity). Some donations to Patient-Led Research for COVID-19 were directed towards graphic design work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UCL Research Ethics Committee [16159.002], and Oregon Health and Science University, Portland, Oregon, USA, with UCL serving as primary site. Weill Cornell Medical College Institutional Review Board (IRB) exemption was obtained. All participants gave informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBased on the UCL Ethics Approval, the raw data cannot be shared publicly. However, anonymised data will become available to all interested parties, after the publication.